MiMedx Group (MDXG) Scheduled to Post Earnings on Tuesday

MiMedx Group (NASDAQ:MDXG) is set to issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. The firm had revenue of $86.83 million for the quarter, compared to the consensus estimate of $85.58 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Up 1.1 %

Shares of NASDAQ:MDXG opened at $6.36 on Tuesday. MiMedx Group has a 1 year low of $3.49 and a 1 year high of $9.27. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11. The business’s 50-day moving average is $7.60 and its 200-day moving average is $7.59. The company has a market capitalization of $934.67 million, a price-to-earnings ratio of 19.88 and a beta of 1.32.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MDXG shares. Mizuho boosted their price target on MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Lake Street Capital initiated coverage on shares of MiMedx Group in a research report on Thursday, March 7th. They set a “buy” rating and a $12.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $12.25.

Insider Buying and Selling at MiMedx Group

In other news, COO Ricci S. Whitlow sold 15,271 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total transaction of $122,320.71. Following the transaction, the chief operating officer now directly owns 401,050 shares of the company’s stock, valued at $3,212,410.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total transaction of $122,320.71. Following the completion of the sale, the chief operating officer now directly owns 401,050 shares of the company’s stock, valued at $3,212,410.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Ricci S. Whitlow sold 15,493 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $8.07, for a total transaction of $125,028.51. Following the completion of the sale, the chief operating officer now owns 416,321 shares in the company, valued at approximately $3,359,710.47. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,145 shares of company stock valued at $409,378. Company insiders own 19.90% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.